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ABSTRACT 
In women, breast carcinoma is the leading cause of cancer death globally. By the combination of better screening and treatments that 
moderately improved the survival however much to be done for the women who are refractory to the current therapies. Among 
Indian females, breast cancer has ranked number one cancer with mortality 12.7 per 100,000 women and age adjusted rate as high as 
25.8 per 100,000 women. Statistics reports from various recent national cancer registries were compared for incidence, mortality 
rates. The age adjusted incidence rate of carcinoma of the breast was found as high as 41 per 100,000 women for Delhi, followed by 
Chennai (37.9), Bangalore (34.4) and Thiruvananthapuram District (33.7). One of the most common factor for the drug resistance in 
breast cancer is high expression of P-glycoprotein (P-gp) which is associated with a poor prognosis in patients. Consequently, P-gp 
represents a potential biomarker of drug resistance. However, a direct role of P-gp as a cause of clinical drug resistance has not been 
adequately tested in breast cancer. The objective of this study was to evaluate the effect of cyclophosphamide with and without 
verapamil on P-gp expression. Verapamil was found specific and effective against P-gp expression in breast cancer. In conclusion, 
treatment efficacy of cyclophosphamide is increased in combination with verapamil against most advanced breast cancer. 
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INTRODUCTION 
In both developing and developed countries, breast 
carcinoma is the most common cancer in the world 
1
. 
The top incidence rate noticed in the high-income 
countries and highest mortality rate noticed in middle-
income countries 
2
. One of the study estimated that in 
2020, the incidence rate of breast cancer will be 1.7 
million and 70% of the breast cancer mortality will 
occur in the developing countries. Hence, breast cancer 
has a incredible public health consequence and the 
reason for that is unavailability of primary prevention, 
efforts to promote early detection should be highlighted 
3
. Worldwide, in female, breast cancer is the most 
common cancer representing closely 25% of all cancers 
with an estimated 1.67 million new cancer cases 
diagnosed in 2012. Women from rural areas have 
somewhat a greater number of cases (883,000) 
compared to developed (794,000) regions 
4
. Compared 
to United Kingdom (95 / 100,000) the age adjusted 
incidence rate of breast cancer is lower (25.8 / 100,000) 
in India but mortality is equivalence (17.1 vs 12.7 per 
100,000) with United Kingdom 
5
. As described in global 
and Indian studies, there is a significant increase in the 
incidence and cancer associated morbidity and mortality 
in Indian subcontinent 
6-10
. In most countries, the 
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prevalence of breast cancer is increasing, and it is 
highlighted that the incidence rate will escalate further 
in the next 20 years in spite of current efforts to prevent 
the disease 
11-13
. Risk factors involves in numbers of 
women with major breast cancer, including late age of 
first pregnancy, shorter or no periods of breastfeeding, 
later menopause, increase in obesity, alcohol 
consumption, inactivity, and hormone replacement 
therapy 
14
. There are many types of chemotherapy used 
to treat breast cancer. Common drugs include: 
Capecitabine, Carboplatin, Cisplatin, 
Cyclophosphamide, Docetaxel, Doxorubicin, etc. 
MDR1 protein (P-gp) is a transmembrane glycoprotein 
with the molecular weight of 170-kDa transmembrane 
glycoprotein. This protein is encoded by the MDR1 
(ABCB1) gene on the human chromosome 7p21. MDR1 
protein overexpression has been associated with 
multidrug resistance in cancer cells including breast 
15
. 
The overexpression of this protein is reason for intrinsic 
and acquired drug resistance in different cancers 
16
. This 
overexpression can reduce intracellular anticancer-drug 
concentration as is frequently associated MDR in human 
cancer cells 
17
. Our knowledge is restricted on how these 
drugs interact with the MDR1 protein. The effects are 
different across cancer types. Breast cancer is one of the 
most common cancers affecting more than one million 
individuals globally. Although, the chemoprevention is 
consequently one of the effective ways to cure breast 
cancer a major concern is potential of drug efflux 
transporter expression, which can significantly affect 
treatment efficacy. Here we hypothesized that down-
regulation of MDR1 may enhance the effectiveness of 
chemotherapy. Recent studies demonstrated that 
verapamil is a calcium ion influx inhibitor and it is a 
well-known molecule developed against cancer chemo-
resistant.  
MATERIALS AND METHODS  
Monolayer culture  
The MCF-7 breast carcinoma cell line was obtained 
directly from the ATCC (Manassas, VA, USA), and 
grown in RPMI (Thermo Fisher Scientific, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (FBS, 
Sigma, St. Louis, MO) at 37°C in a 5% humidified CO2 
incubator. Characterization of cell line was done 
according to their surface expression phenotype. MCF-7 
cell lines were grown for 48 hours with 80% 
confluency. After that the same cell lines were treated 
with Verapamil for 72 hours. These cells were used to 
form 3D tumorospheres along with controls. Verapamil 
and Cyclophosphamide was purchased from 
Selleckchem (USA). 
Tumorosphere culture  
Single cell suspensions were plated in 6-well tissue 
culture plates covered with poly-2 
hydroxyethylmethacrylate (Sigma, St. Louis, MO) to 
prevent cell attachment, at a density of 1,000 cells/ml in 
serum free RPMI supplemented with 1% L-glutamine, 
1% penicillin/streptomycin, 30% F12 (Sigma), 2% B27 
(Thermo Fisher Scientific, Carlsbad, CA), 20 ng/ml 
recombinant human epidermal growth factor  (EGF; 
Sigma, St. Louis, MO) and 20 ng/ml recombinant 
human fibroblast growth factor  (FGF; Thermo Fisher 
Scientific, Carlsbad, CA). The medium was made semi-
solid by the addition of 0.5% Methylcellulose (R&D 
Systems, Minneapolis, MN) to prevent cell aggregation. 
After 7 days in culture, 3D tumorospheres were 
collected by gentle centrifugation (200 x g) and 
dissociated enzymatically (5 min in 1:1 trypsin/RPMI 
solution at 37°C) and mechanically by passing through a 
25G needle (6 strokes). Single cells were re-plated at a 
density. 
Cell kinetic assay  
MCF-7 cells were grown in a 96-well tissue culture 
plate with drugs and appropriate controls. Subsequently 
they were incubated with the WST-1 reagent (Dojindo 
Inc, Japan) for 4 hours. After this incubation period, the 
formazan dye formed was quantitated with a multi well 
spectrophotometer (ELISA reader). The measured 
absorbance directly correlates to the number of viable 
cells. 
Cytotoxicity assay  
MCF-7 cells cultured as monolayers or tumorospheres 
were treated with verapamil, cyclophosphamide for 3 
days and cell death were measured with LDH 
cytotoxicity assay (Biovision, USA).  
Flow cytometry  
PerCP-conjugated CD44, BV711-conjugated CD24 
monoclonal antibody was purchased from BD 
Bioscience. After 3 days of drug treatment the MCF-7 
cells were dissociated with 0.25 % trypsin- EDTA (1 
mM) (Invitrogen) for 3 min and washed with Calcium 
and magnesium free dulbecco phosphate buffered saline 
solution by spinning at 400g for 7 minutes. Then these 
cells were diluted in 100 μl FACS buffer (PBS 
containing 1 % fetal calf serum) and then incubated for 
1 hr at 4° C in FACS buffer with the corresponding 
mAb: anti-CD44-PerCP, CD24-BV711. Flow cytometry 
analysis was performed with a BD FACS Caliber II flow 
cytometer (BD Biosciences). 
Statistical Analysis  
Data was expressed as mean standard deviation. Statisti-
cal packages for social sciences (SPSS) (SPSS UK Ltd, 
Woking, Surrey, UK) was used for data analysis. Chi-
square analysis was used to assess significant changes 
between different groups. The level of significance was 
set at P ≤ 0.05 and analysis of variance (one-way 
ANOVA) was used to compare the means of different 
groups.  
4. RESULTS  
CPA promotes P-gp expression 
We examined the expression of P-gp in MCF-7 cell line 
with or without CPA. We treated the MCF-7 cell line 
with CPA for 48 hrs and we checked the P-gp 
expression using flow cytometry. We noticed significant 
increase in P-gp expression when compared to the 
control. However, in control the expression of P-gp was 
unchanged.  
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Figure 1: Increased level of CSC in CPA treated cells 
and in turn the expression of P-gp in MCF-7 cell 
lines. 
Targeting CSC by using Verapamil 
We confirmed that CPA alone is inducing the 
expression of both P-gp and CSC in MCF-7 cell line. 
So, we have decided to supress the expression of CSC 
by using P-gp inhibitor. We have treated the MCF-7 cell 
line with and without verapamil and we have maintained 
the cells for 9 days to check the formation of 
tumorosphere. The tumorosphere culture showed that 
the MCF-7 cell line treated with verapamil has failed to 
form tumorosphere and on the other hand the control 
cells formed tumorosphere. 
 
 
Figure 2: Verapamil a treated cell fails to form 3D tumorospehere against untreated 
 
Correlation between P-gp and CSC 
We then thought to correlat the expression of P-gp with 
cancer stem cell markers (CD44+ and CD24-). For that 
we have treated the MCF-7 cell line with CPA for 2 
days and we checked the expression of both P-gp and 
CD44+/CD24- using flow cytometry. We observed that 
in control arm, the expression of both P-gp and 
CD44+/CD24- were unchanged. However, in the CPA 
treated arm the expression of P-gp and CD44+/CD24- 
were significantly increased when compared untreated 
arm.
 
 
Figure 3: CPA treated cells increases the CD44+/CD24- expression against control 
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Targeting P-gp by using Verapamil  
We confirmed that CPA alone is inducing the 
expression of P-gp and CSC in MCF-7 cell line. To 
supress the expression of P-gp and CSC, we have 
chosen Verapamil (P-gp inhibitor). We have treated the 
MCF-7 cell line with and without verapamil for 48 
hours and we have carried out the flow cytometry 
analysis from the verapamil treated MCF-7 cell line. 
The flow cytometry data demonstrated that the MCF-7 
cell line treated with verapamil has significant decrease 
in P-gp expression and also noticed decreased 
expression of CSC from the verapamil treated arm. But 
in the verapamil untreated arm, the expression of both 
P-gp and CD44+/CD24+ were unchanged in MCF-7 
cell line. 
Viability of MCF-7 Cell line in the presence of 
Verapamil (P-gp inhibitor) 
After 3 days of verapamil treatment, MCF-7 cell lines 
were measured for the viability by WST-1 method. We 
observed very minimal or negligible difference 
between control and verapamil treated cell lines, and 
the same was observed in the morphological images 
under inverted microscope (data not shown here). This 
result indicates, verapamil alone play a vital role in 
suppressing the P-gp inhibitor and it did not affect the 
viability of the cells.    
 
Figure 4: Viability of CPA and CPA + Verapamil 
treated cells 
Combination of Chemo with verapamil improves 
Cytotoxicity 
We have got convincing data that verapamil alone has 
not affected the viability of MCF-7 cells. So, further 
we treated the MCF-7 cell line in combination with 
verapamil and CPA. Then we measured the cell death 
by LDH cytotoxicity assay. This experiment showed us 
that, combination of both P-gp inhibitor and 
chemotherapy drug drastically affect the viability of 
MCF-7 cell line.  
 
Figure 5: Cytotoxicity of CPA Vs CPA+ Verapamil 
treated cells 
DISCUSSION 
Like in most of the cancers, breast cancer also fails to 
respond to their current chemotherapies (12). The 
intrinsic and extrinsic resistance are contributed by P-
glycoproteins. Here we set out to understand the 
relationship between the conventional chemotherapy 
(cyclophosphamide) and an inhibitor of 
transmembrane flux of calcium ions (verapamil). 
When combined with chemotherapeutic agent 
verapamil can help to promote intracellular drug 
accumulation. Treatment of cells along with P-gp 
inhibitor represents a potential strategy to improve the 
clinical outcomes. 
Recent understanding of the drug resistance facilitated 
mechanisms underlying the treatment failures in breast 
cancer (16). Treating breast cancer using conventional 
chemotherapy along with P-.gp inhibitor like 
verapamil increases the drug sensitiveness. In this 
context, verapamil decreases P-glycoprotein and 
cancer stem cell expressions in MCF-7 cell lines. The 
same was shown in tumorospheres as well. When 
verapamil used the viability was not reduced, whereas 
when verapamil and CPA used combined the viability 
was drastically decreased. Deregulation of P-
glycoprotein may be an important clinical and 
pathologic feature of breast cancer and a predictor of 
poor overall survival (15). In this study, we treated 
MCF-7 cell lines with verapamil, an inhibitor of p-
glycoprotein that resulted in decreased levels of the 
stem cell markers CD44+/CD24-. 
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